of 200 mg and a maintenance dose of 100 mg via IV infusion every day) was added because the C. tropicalis was resistant to fluconazole (minimum inhibition concentration of 64 mg/L) as determined using the broth microdilution method. However, on the 22nd day of hospitalization, the blood cultures from the central venous catheter (CVC) and peripheral blood samples yielded R. mucilaginosa. The organism was identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS Biotyperä, Bruker Daltonik GmbH, Bremen, Germany) with an identification score value of 2.165. The antifungal agent was changed to 250 mg of liposomal amphotericin B stat, and a maintenance dose of 200 mg via IV infusion every day. Unfortunately, the patient died on the 25th day of hospitalization due to refractory septic shock.
R. mucilaginosa is an agent of opportunistic infection in immunocompromised patients; it is associated with high mortality despite antifungal treatments, particularly in patients who receive indwelling foreign catheter implantations such as PTGBD or central venous catheters.
1e3,5 R. mucilaginosa is a non-Candida unicellular pigmented yeast (Fig. 1B) part of the phylum Basidiomycota, which has been isolated from blood, skin, and environmental specimens. Clinical manifestations of R. mucilaginosa infections include bloodstream infection, peritonitis, meningitis, and central venous catheter-related infections. In general, Rhodotorula spp. isolates are less susceptible to echinocandin agents (caspofungin, micafungin, and anidulafungin), like Zygomycetes, Trichosporon, and Cryptococcus spp., due to the lack of 1,3-b-D glucan in their cell walls. As a result, patients undergoing treatment with echinocandins have been reported to have breakthrough fungal infections caused by these organisms. Modern therapeutic modalities and invasive procedures in critically ill patients have an increased risk of opportunistic fungemia.
infections have emerged as a major clinical issue. 4 The risk of R. mucilaginosa fungemia should not be overlooked in patients with risk factors and those receiving echinocandin therapy. 
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